GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Suzhou Basecare Medical Corp Ltd (HKSE:02170) » Definitions » Peter Lynch Fair Value

Suzhou Basecare Medical (HKSE:02170) Peter Lynch Fair Value : HK$-11.89 (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Suzhou Basecare Medical Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Suzhou Basecare Medical's PEG is 1. Suzhou Basecare Medical's 5-Year TTM EBITDA Growth Rate is 15.73. Suzhou Basecare Medical's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.76. Therefore, the Peter Lynch Fair Value for today is HK$-11.89.

As of today (2024-12-15), Suzhou Basecare Medical's share price is HK$2.85. Suzhou Basecare Medical's Peter Lynch fair value is HK$-11.89. Therefore, Suzhou Basecare Medical's Price to Peter Lynch Fair Value Ratio for today is N/A.


The historical rank and industry rank for Suzhou Basecare Medical's Peter Lynch Fair Value or its related term are showing as below:



HKSE:02170's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.78
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Suzhou Basecare Medical Peter Lynch Fair Value Historical Data

The historical data trend for Suzhou Basecare Medical's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Basecare Medical Peter Lynch Fair Value Chart

Suzhou Basecare Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial - - - - -

Suzhou Basecare Medical Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Suzhou Basecare Medical's Peter Lynch Fair Value

For the Medical Devices subindustry, Suzhou Basecare Medical's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Basecare Medical's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Suzhou Basecare Medical's Price-to-Peter-Lynch-Fair-Value falls into.



Suzhou Basecare Medical Peter Lynch Fair Value Calculation

Suzhou Basecare Medical's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 15.73 *-0.756
=-11.89

For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Suzhou Basecare Medical's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.76.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Suzhou Basecare Medical  (HKSE:02170) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 15.73 instead of 15 in this case.

Suzhou Basecare Medical's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=2.85/-11.89
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suzhou Basecare Medical Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Suzhou Basecare Medical's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Suzhou Basecare Medical Business Description

Traded in Other Exchanges
N/A
Address
BioBay, No. 218 Xinghu Street, Unit 101, Building A3, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000
Suzhou Basecare Medical Corp Ltd is engaged in providing genetic testing solutions for assisted human reproduction. The company generates revenues from Sales of testing kits, followed by Sales of testing devices, instruments, and consumables. Basecare focuses on the assisted reproductive sector, such as pre-implantation genetic screening and diagnosis, non-invasive prenatal DNA testing, and chromosome abnormalities testing. Geographically the company generates the majority of its revenue from the PRC.
Executives
Orbimed Capital Llc 2102 Investment manager
Lake Bleu Prime Healthcare Master Fund Limited 2201 Interest of corporation controlled by you
Orbimed Partners Master Fund Limited 2101 Beneficial owner
Dawn Capital Fund 2101 Beneficial owner
Dawn Capital Limited 2102 Investment manager
Hh Spr-xiv Cy Holdings Limited 2201 Interest of corporation controlled by you
Hh Spr-xiv Hk Holdings Limited 2101 Beneficial owner
Hh Spr-xiv Holdings L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager

Suzhou Basecare Medical Headlines

No Headlines